Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00452439 · ClinicalTrials.gov registry record · Phase 3
A Study of Actonel for the Prevention of Bone Loss
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 72
- Enrollment target
NCT00452439: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00452439 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 72 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00452439, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 72 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if Actonel (risedronate) can help to prevent the development of osteoporosis (brittle and weak bones) caused by the steroid medication used to treat leukemia. The safety of this treatment in patients with ALL or LL will also be studied.
Interventions
- DIETARY_SUPPLEMENT Vitamin D
- DIETARY_SUPPLEMENT Calcium
- DRUG Actonel (Risedronate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2004-02 |
| Est. Completion | 2014-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00452439
The ClinicalTrials.gov registry entry for NCT00452439 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vitamin D is the first listed.
NCT00452439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00452439 about?
NCT00452439 is a clinical study titled "A Study of Actonel for the Prevention of Bone Loss". The goal of this clinical research study is to learn if Actonel (risedronate) can help to prevent the development of osteoporosis (brittle and weak bones) caused by the steroid medication used to treat leukemia. The safety of this treatment in patients with ALL or LL will also be studied.
What is the current status of trial NCT00452439?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 72 participants. The study started on 2004-02. Estimated completion is 2014-08.
What interventions are being tested in trial NCT00452439?
The interventions under investigation include: Vitamin D (DIETARY_SUPPLEMENT), Calcium (DIETARY_SUPPLEMENT), Actonel (Risedronate) (DRUG).
Who is sponsoring clinical trial NCT00452439?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.